Cantor Fitzgerald Has Weak Outlook for ASND FY2025 Earnings

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Ascendis Pharma A/S in a research note issued to investors on Tuesday, May 6th. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will earn ($4.42) per share for the year, down from their prior forecast of ($2.72). Cantor Fitzgerald currently has a "Overweight" rating and a $200.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($4.34) per share.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million.

A number of other research firms have also weighed in on ASND. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Royal Bank of Canada boosted their price target on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Wedbush upped their target price on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $180.00 to $250.00 in a research note on Monday. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $216.07.

Ascendis Pharma A/S Stock Down 0.9 %

NASDAQ ASND opened at $161.34 on Thursday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The business has a 50 day moving average price of $155.96 and a two-hundred day moving average price of $141.00. The stock has a market cap of $9.84 billion, a PE ratio of -22.72 and a beta of 0.41.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Ascendis Pharma A/S by 54.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock valued at $375,226,000 after buying an additional 960,504 shares in the last quarter. Capital International Investors raised its position in shares of Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after purchasing an additional 753,859 shares during the period. RA Capital Management L.P. boosted its holdings in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after buying an additional 402,316 shares during the period. Vestal Point Capital LP raised its holdings in Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock worth $71,588,000 after acquiring an additional 270,000 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in Ascendis Pharma A/S by 4.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after acquiring an additional 193,688 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.